Queeley Gilbert L, Campbell Ellen S
Research Associate, Division of Economic Social and Administrative Pharmacy, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee.
Associate Professor, Division of Economic Social and Administrative Pharmacy, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee.
Am Health Drug Benefits. 2018 May;11(3):118-127.
End-stage renal disease (ESRD) imposes significant economic and social burdens on patients and healthcare systems. In the United States alone, more than 600,000 Americans have ESRD, with an estimated annual cost of treatment of more than $30 billion. Peritoneal dialysis and hemodialysis are competing renal replacement therapies in ESRD; however, data comparing quality-of-life outcomes between these 2 modalities are limited.
To compare the effectiveness of peritoneal dialysis with the more common treatment modality of hemodialysis on the health-related quality of life (HRQoL) of patients with ESRD in the general, physical, and psychological domains; and to determine whether the time of publication and the origin of each study influenced its findings regarding the effectiveness of the 2 modalities.
This meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to collect the data. PubMed, MEDLINE, and PsycINFO were the primary databases searched. Only articles published in English were included in this meta-analysis. The measure of effect size was Cohen's standardized mean difference. A random-effects model was used to test the hypothesis of equality in the mean HRQoL.
A total of 15 studies with a combined sample size of 4318 patients met the study criteria and were included in the analysis. The pooled effect sizes based on the random-effects model were 0.24 (95% confidence interval [CI], -0.17-0.66) in the general domain; 0.10 (95% CI, -0.09-0.29) in the physical-functioning domain; and 0.29 (95% CI, -0.13-0.71) in the psychological-functioning domain. None of the summary effect sizes was statistically significant. Subgroup analyses favored peritoneal dialysis regarding the time and country of publication.
The majority of the studies included in this analysis favored peritoneal dialysis over hemodialysis in all 3 domains. However, the pooled effect sizes were not significant, resulting in the inability to conclude that peritoneal dialysis is the more effective of these 2 treatment modalities.
终末期肾病(ESRD)给患者和医疗系统带来了巨大的经济和社会负担。仅在美国,就有超过60万美国人患有ESRD,估计每年的治疗费用超过300亿美元。腹膜透析和血液透析是ESRD中相互竞争的肾脏替代疗法;然而,比较这两种治疗方式生活质量结果的数据有限。
比较腹膜透析与更常见的血液透析治疗方式对ESRD患者在总体、身体和心理领域与健康相关生活质量(HRQoL)的有效性;并确定每项研究的发表时间和来源是否影响其关于这两种治疗方式有效性的研究结果。
本荟萃分析遵循系统评价和荟萃分析的首选报告项目指南来收集数据。主要检索的数据库为PubMed、MEDLINE和PsycINFO。本荟萃分析仅纳入以英文发表的文章。效应量的衡量指标为科恩标准化平均差。采用随机效应模型检验平均HRQoL相等的假设。
共有15项研究符合研究标准,纳入分析的样本总量为4318例患者。基于随机效应模型的合并效应量在总体领域为0.24(95%置信区间[CI],-0.17 - 0.66);在身体功能领域为0.10(95% CI,-0.09 - 0.29);在心理功能领域为0.29(95% CI,-0.13 - 0.71)。所有汇总效应量均无统计学意义。亚组分析在发表时间和国家方面更支持腹膜透析。
本分析中纳入的大多数研究在所有三个领域都更倾向于腹膜透析而非血液透析。然而,合并效应量并不显著,因此无法得出腹膜透析是这两种治疗方式中更有效的结论。